Medpace
NASDAQ: MEDP
Stock price
493.53 USD
(+185.77%) 5 years
Financial Performance
5Y price score: 285
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.
10Y return: 1,675.9%
US$ Per
Share
Earnings per share
Free cash flow per share
Stock price
By default your notes are visible only to you.
250.0
52-week range
628.9
Your model inputs
| Required return / cost of capital |
| FCFF terminal growth rate |
Valuation
Free Cash Flow Yield
4.8 %
Dividend Yield TTM
-
Market cap $
$ 14,094.2
Price / Earnings TTM
32.2
Price / Book TTM
30.4
PEG TTM
1.5
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
74.8 %
185.8 %
1,675.9 %
Free cash flow per share growth
29.2 %
283 %
1,052.6 %
Earnings per share growth
21 %
297.9 %
5,557.1 %
Founded: 1,992
Employees: 5,900
Business Summary:
all figures in USD Millions except per share data
Periods:
View:
Forecast:
Averages
based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.
Analysts
Average Revenue and Net Income forecast estimates from analysts who cover the stock.
Custom
you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.
ㅤ
Please log in / sign up view historical financials. It is free under TopFunds
Light plan.
Increase
Decrease
Total
| Required return / cost of capital |
| FCFF terminal growth rate |
| Free cash flow forecast |
| Terminal value |
| ㅤPV breakdown |
| Enterprise value / PV of FCF |
| ㅤPlus / (Less): Net Debt |
| ㅤLess: preferred stock |
| ㅤLess: minority interest |
| Market cap |
| ㅤNumber of shares |
| Price per share |
Please log in / sign up to calculate fair value based on selected inputs
Latest Earnings Call Takeaways
2025 Q4 (Feb 10, 2026)
1) Strategy & Leadership
- CEO August Troendle noted an elevated cancellation rate in Q4, leading to a lower than expected net book-to-bill ratio of 1.04.
- Despite cancellations, the overall business environment is rated as adequate and improving.
- The company continues to see good opportunities, particularly in oncology and metabolic areas, although cancellations were skewed towards metabolic projects.
2) Financial & Segment Results
- Q4 revenue reached $708.5 million, a 32% increase YoY, while full-year revenue was $2.53 billion, up 20% from 2024.
- Net new business awards in Q4 were $736.6 million, a 39.1% increase YoY, with a full-year total of $2.65 billion, up 18.7%.
- Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase YoY, with an expected $1.9 billion to convert to revenue in the next twelve months.
- Q4 EBITDA was $160.2 million (22.6% margin), up from $133.5 million (24.9% margin) YoY. Full-year EBITDA was $557.7 million, a 16.1% increase YoY.
- Net income for Q4 was $135.1 million, a 15.5% increase YoY, with full-year net income at $451.1 million, an 11.6% increase YoY.
3) Problems / Headwinds
- Elevated cancellations in Q4 were the highest in over a year, impacting the net book-to-bill ratio and overall revenue expectations.
- Cancellations were widespread, particularly in the metabolic area, but no single large project was responsible.
- The company faced pressure on EBITDA margins due to higher reimbursable costs driven by the therapeutic mix.
4) Operational Plans & Guidance
- For 2026, the company expects total revenue between $2.755 billion and $2.855 billion, representing growth of 8.9% to 12.8% over 2025.
- EBITDA guidance for 2026 is set between $605 million and $635 million, reflecting growth of 8.5% to 13.9%.
- Net income is projected to be between $487 million and $511 million, with expected earnings per diluted share of $16.68 to $17.50.
- The company anticipates accelerated hiring in 2026, with mid to high single-digit growth in headcount.
5) Investor Angle & Missing Information
- The company did not provide specific guidance on direct service revenue or detailed metrics on RFP activity and win rates.
- There was no mention of how the elevated cancellation rates might impact future revenue projections beyond 2026.
Bottom line: Medpace Holdings, Inc. has demonstrated strong revenue growth and a solid backlog, but elevated cancellation rates in Q4 present a near-term challenge. The company is optimistic about its operational plans and guidance for 2026, indicating continued growth potential, albeit with caution regarding the impact of cancellations and market dynamics.
Medpace — Financial Overview, Stock Price, Market Cap
Medpace is a company. Founded in 1992. As of April 13, 2026, the company's market capitalization is $14094229740 with a current stock price of $493.53.